Xu Hui, Zhang Jin, Cheng Xiaomiao, Zhou Qiaoling
Department of Nephrology, Xiangya Hospital, Central South University, Changsha 410008, China
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2013 Sep;38(9):920-4. doi: 10.3969/j.issn.1672-7347.2013.09.009.
To investigate the calcium-phosphate metabolic condition in maintenance hemodialysis patients with chronic kidney disease (CKD), and to observe the effect of large dose calcitriol on secondary hyperparathyroidism (SHPT).
We tested and compared the serum levels of calcium, phosphate, intact parathyroid hormone (iPTH), and alkaline phosphatase (AKP) in hemodialysis patients at different hemodialysis time (Group A with hemodialysis period ≤3 years and Group B with hemodialysis period >3 years). We also detected those indexes before and after treating SHPT with large dose calcitriol. Twenty SHPT patients were divided into Group I (enlargement of parathyroid gland or nodule detected by color Doppler ultrasound) and Group II (normal parathyroid gland detected by color Doppler ultrasound).
In the maintenance hemodialysis patients, the serum phosphate was (2.11±0.38) mmol/L and iPTH was (581.11±487.75) pg/mL. The serum level of iPTH in Group B was higher than that in Group A [(828.13±690.39) pg/mL vs (477.94±324.73) pg/mL, P<0.001]. In Group I, the serum level of iPTH [before vs after: (2471.7±898.3) pg/mL vs (2510.4±825.7) pg/mL] and AKP [before vs after: (524.2±18.8)U/L vs (511.3±19.3)U/L] did not change after the treatment of large dose calcitriol (P>0.05). In Group II, the serum level of iPTH [before vs after: (1358.5±302.8) pg/mL vs (369.3±43.4) pg/mL, P<0.001] and AKP [before vs after: (565.9±23.9)U/L vs (234.8±21.1)U/L, P<0.001] decreased significantly after the treatment of large dose calcitriol.
Patients with longer time of hemodialysis have a higher level of iPTH. Large dose calcitriol can improve the clinical syndrome of SHPT, and decrease the level of iPTH and AKP in SHPT patients with normal parathyroid gland.
探讨维持性血液透析慢性肾脏病(CKD)患者的钙磷代谢状况,观察大剂量骨化三醇对继发性甲状旁腺功能亢进(SHPT)的影响。
检测并比较不同血液透析时间的血液透析患者(A组血液透析时间≤3年,B组血液透析时间>3年)的血清钙、磷、全段甲状旁腺激素(iPTH)及碱性磷酸酶(AKP)水平。同时检测大剂量骨化三醇治疗SHPT前后的上述指标。20例SHPT患者分为I组(彩色多普勒超声检查发现甲状旁腺增大或有结节)和II组(彩色多普勒超声检查甲状旁腺正常)。
维持性血液透析患者血清磷为(2.11±0.38)mmol/L,iPTH为(581.11±487.75)pg/mL。B组血清iPTH水平高于A组[(828.13±690.39)pg/mL对(477.94±324.73)pg/mL,P<0.001]。I组大剂量骨化三醇治疗后血清iPTH水平[治疗前对治疗后:(2471.7±898.3)pg/mL对(2510.4±825.7)pg/mL]及AKP水平[治疗前对治疗后:(524.2±18.8)U/L对(511.3±19.3)U/L]无变化(P>0.05)。II组大剂量骨化三醇治疗后血清iPTH水平[治疗前对治疗后:(1358.5±302.8)pg/mL对(369.3±43.4)pg/mL,P<0.001]及AKP水平[治疗前对治疗后:(565.9±23.9)U/L对(234.8±21.1)U/L,P<0.001]显著下降。
血液透析时间较长的患者iPTH水平较高。大剂量骨化三醇可改善SHPT的临床症状,并降低甲状旁腺正常的SHPT患者的iPTH及AKP水平。